- Jim Rogers   Jul 25, 2017 at 08:04: AM
Jim Rogers
new user
Merck said that its anti-PD1 drug Keytruda (pembrolizumab) failed to meet the primary endpoint in the Phase III KEYNOTE-040 trial for previously treated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). http://alph.st/b4ea1232